Drug Search Results
More Filters [+]

Eniluracil

Alternative Names: eniluracil, adh-300004, adh300004, adh 300004, PCS6422, PCS-6422, PCS 6422
Latest Update: 2024-06-12
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DPD Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Fennec Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eniluracil

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Gastrointestinal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PCS6422-GI-01

P1

Active, not recruiting

Gastrointestinal Cancer

2024-06-29

27%

Recent News Events